Journal of Thoracic Oncology · 2019 · 83 citations · 43 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsImmuno-oncology BiomarkersTumor-infiltrating LymphocytesCytotoxic T Lymphocyte InfiltrationImmune Infiltration Prognostic SignaturesPrognostic VariablesProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 UpregulationTissue MicroarraysTumor Immune Cell Infiltration
43
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text